 reuters    dr  scott gottlieb  a partner at one of the world s largest venture capital funds and a former deputy commissioner at the u s  food and drug administration  is being considered by president elect donald trump to run the agency  according to sources close to the transition team      gottlieb    a venture partner at new enterprise associates and resident fellow at the american enterprise institute  a conservative think tank based in washington  is well known in health policy circles and is a frequent commentator on television and in print      gottlieb is being considered alongside jim o neill  a self declared libertarian and colleague of peter thiel  the co founder of mithril capital management who was an early trump supporter and is now advising his transition team  bloomberg news first reported that trump was looking at o neill   trump  a republican  takes office on jan    michael gaba  federal policy leader of law firm holland   knight s national healthcare   life sciences team  said gottlieb would be more palatable to more people than o neill  who believes drugs should be allowed on the market before their efficacy has been established  as long as they are safe  even the drug industry would likely oppose that stance  gaba said  since companies want to be able to make credible claims that their products are effective in treating the diseases they say do   they want the fda s good housekeeping seal of approval   gaba said last week  adding  however  that drug makers would like to provide less data to get it  gottlieb would be a more traditional choice than o neill and fits the profile of what trump s administration seems to be looking for  he said   he leans right  he s got experience in the agency  he s got the m d  credential  and he s outspoken   gaba said  the fda historically has named someone with medical credentials to head the agency  o neill has none  though he served as principal associate deputy secretary of health and human services under the george w  bush administration  gottlieb s ties to the pharmaceutical industry run deep  he sits on the boards of multiple companies and advises others  including the british pharmaceutical giant glaxosmithkline plc  he is also a managing director of investment banking at t r  winston   co  a los angeles based  privately held investment bank that focuses on healthcare  clean energy and consumer technology  according to its website  the firm provides services to a range of healthcare clients   including companies engaged in the clinical development of new therapeutic compounds  drug discovery techniques  medical technologies  and devices   between  and  gottlieb was a senior adviser to the fda commissioner and then the agency s director of medical policy development  in  he also acted as senior adviser to the centers for medicare and medicaid services  from   he was the fda s deputy commissioner for medical and scientific affairs  gottlieb has a medical degree from mount sinai school of medicine and a bachelor s degree in economics from wesleyan university  he advises the u s  department of health and human services as a member of the federal health information technology policy committee  